Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001000753 | SCV001012350 | likely benign | Smith-Lemli-Opitz syndrome | 2024-11-28 | criteria provided, single submitter | clinical testing | |
ARUP Laboratories, |
RCV001000753 | SCV001157804 | uncertain significance | Smith-Lemli-Opitz syndrome | 2018-08-16 | criteria provided, single submitter | clinical testing | The DHRC7 c.765C>T; p.Phe255Phe variant (rs200132007), to our knowledge, is not reported in the medical literature or gene specific databases. This variant is found in the non-Finnish European population with an overall allele frequency of 0.03% (41/126634 alleles) in the Genome Aggregation Database. This is a synonymous variant in a weakly conserved nucleotide, but computational analyses (Alamut v.2.11) predict that this variant may impact splicing by strengthening a cryptic splice acceptor site. If splicing occurs at this cryptic site, it would be predicted to remove 143 nucleotides and cause a frameshift; however, mRNA studies would be required to confirm this. Due to limited information, the clinical significance of the p.Phe255Phe variant is uncertain at this time. |
Illumina Laboratory Services, |
RCV001000753 | SCV001267479 | uncertain significance | Smith-Lemli-Opitz syndrome | 2017-04-27 | criteria provided, single submitter | clinical testing | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). No publications were found based on this search. Allele frequency data from public databases did not allow this variant to be ruled in or out of causing disease. Therefore, this variant is classified as a variant of unknown significance. |
Gene |
RCV001546710 | SCV001766277 | likely benign | not provided | 2021-06-21 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002390816 | SCV002671804 | likely benign | Inborn genetic diseases | 2022-10-23 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Ce |
RCV001546710 | SCV005330781 | likely benign | not provided | 2024-08-01 | criteria provided, single submitter | clinical testing | DHCR7: BP4, BP7 |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV004782586 | SCV005395808 | likely benign | not specified | 2024-09-17 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV001000753 | SCV001458010 | uncertain significance | Smith-Lemli-Opitz syndrome | 2018-06-23 | no assertion criteria provided | clinical testing |